Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma

Journal of Chemotherapy

Volumn 21, Issue 2, 2009, Pages 205-210

  Ferrari, Stefano ^a   Palmerini, Emanuela ^a   Staals, Eric ^b   Abate, M E ^b   Longhi, Alessandra ^a   Cesari, Marilena ^a   Balladelli, A ^c   Pratelli, Loredana ^c   Bacci, G ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b 5th Orthopedic Division   (Italy)

^c Laboratory of Oncologic Research Department of Musculoskeletal Oncology   (Italy)

Author keywords

Adults; AYA; Chemotherapy related toxicity; Children; Osteosarcoma; Sex

Indexed keywords

CISPLATIN; DOXORUBICIN; FOLINIC ACID; IFOSFAMIDE; MESNA; METHOTREXATE;

ADOLESCENT; ADULT; ARTICLE; BRAIN TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CHILD; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; DRUG EXCRETION; DRUG MEGADOSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; GROUPS BY AGE; HOSPITALIZATION; HUMAN; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; OSTEOSARCOMA; PEDIATRICS; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRESCHOOL CHILD; SCHOOL CHILD; SEX DIFFERENCE; THROMBOCYTOPENIA;

EID: 84983161226     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2009.21.2.205     Document Type: Article

References (23)

1. Campanacci M. High grade osteosarcomas. In: Bone and soft tissue tumors, 2 ed. Wien, New York: Springer-Verlag, 1999: 463-515
2. Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol. 2007; 19 (6): 341-6
3. Hurria A, Lichtman SM. Pharmacokinetics of chemotherapy in the older patient. Cancer Control. 2007; 14 (1): 32-43
4. Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther. 2007; 82 (1): 87-96
5. Stephenson T. How children's responses to drugs differ from adults. Br J Clin Pharmacol. 2005; 59 (6): 670-3
6. Verrill MW, Judson IR, Wiltshaw E, Thomas JM, Harmer CL, Fisher C. The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours. Ann Oncol. 1997; 8 (11): 1099-105
7. Singh S, Parulekar W, Murray N, Feld R, Evans WK, Tu D et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol. 2005; 23 (4): 850-6
8. Klimm B, Reineke T, Haverkamp H, Behringer K, Eich HT, Josting A et al. German Hodgkin Study Group. Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. J Clin Oncol. 2005; 23 (31): 8003-11
9. Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P et al. Italian and Scandinavian Sarcoma Groups. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 2005; 23 (34): 8845-52
10. Pollock BH, Birch JM. Registration and classification of adolescent and young adult cancer cases. Pediatr Blood Cancer 2008; 50 (5 suppl): 1090-1093
11. Eselgrim M, Grunert H, Kuhne T, Zoubek A, Kevric M, Burger H et al. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials. Pediatr Blood Cancer. 2006; 47 (1): 42-50
12. Lewis IJ, Weeden S, Machin D, Stark D, Craft AW. Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup. J Clin Oncol. 2000; 18 (24): 4028-37
13. Juergens C, Weston C, Lewis I, Whelan J, Paulussen M, Oberlin O et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial Pediatr Blood Cancer. 2006; 47 (1): 22-9
14. Scripture CD, Sparreboom A, Figg WD. Modulation of cytochrome P450 activity: Implications for cancer therapy. Lancet Oncol 2005, 6 (10): 780-789
15. Fujita K. Cytochrome P450 and anticancer drugs. Curr Drug Metab 2006, 7 (1): 23-37
16. Bebia Z, Buch SC, Wilson JW, Frye RF, Romkes M. Cec-chetti A et al: Bioequivalence revisited: Influence of age and sex on CYP enzymes. Clin Pharmacol Ther 2004, 76 (6): 618-627
17. Hempel G, Flege S, Wurthwein G, Boos J. Peak plasma concentrations of doxorubicin in children with acute lym-phoblastic leukemia or non-Hodgkin lymphoma. Cancer Chemother Pharmacol 2002, 49 (2): 133-41
18. Eksborg S, Palm C, Bjork O. A comparative pharmacoki-netic study of doxorubicin and 4'-epi-doxorubicin in children with acute lymphocytic leukemia usign a limited sampling procedure. Anticancer Drugs 2000, 11 (2):129-136
19. Frost BM, Eksborg S, Bjork O, Abrahamsson J, Behrendtz M, Castor A et al: Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: Multi-institutional collaborative study. Med Pediatr Oncol 2002, 38 (5): 329-337
20. Chen CS, Lin JT, Goss KA, He YA, Halpert JR, Wax-man DJ. et al. Activation of the anticancer prodrugs cyclophos-phamide and ifosfamide: Identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol Pharmacol 2004, 65 (5): 1278-1285
21. Furlanut M, Franceschi L. Pharmacology of ifos-famide.Oncology. 2003; 65 Suppl 2:2-6.
22. Boddy AV, Yule SM, Wyllie R, Price L, Pearson AD, Idle JR. Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration. Cancer Chemother Pharmacol. 1996; 38 (2): 147-54
23. Dobbs NA, Twelves CJ, Gillies H, James CA, Harper PG. Rubens RD.Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol 1995, 36 (6): 473-476